Sfoglia per Soggetto "Daptomycin"
Items 1-5 di 5
-
Clinical effectiveness, safety profile, and pharmacokinetics of daptomycin in pediatric patients: A systematic review
(2016)Infections by Gram-positive pathogens pose a public health risk, especially due to increasing antibiotic resistance. Daptomycin has efficacy against most clinically important Gram-positive bacteria. Although experience ... -
Clinical Experience with Daptomycin for the Treatment of Gram-positive Infections in Children and Adolescents
(2016)Background: This subgroup analysis of the European Cubicin Outcomes Registry Experience evaluated the safety and effectiveness of daptomycin in children and adolescent patients (<18 years). Methods: Clinical outcomes at ... -
Daptomycin for the treatment of osteomyelitis and orthopaedic device infections: real-world clinical experience from a European registry
(2016)Osteomyelitis is a serious infection predominantly caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). Orthopaedic device-related infections are complex and require a careful ... -
Daptomycin Use in Children: Experience with Various Types of Infection and Age Groups
(2017)Background: In Greece, there are high rates of methicillin (40%-60%) and clindamycin (15%-25%) resistance among community-acquired Staphylococcus aureus isolates. Therefore, we sought to identify other antimicrobial treatment ... -
Evaluation of Effectiveness and Safety of High-Dose Daptomycin: Results from Patients Included in the European Cubicin® Outcomes Registry and Experience
(2015)Introduction: Daptomycin, a rapid concentration-dependent bactericidal antibiotic, is approved at a dose of 4 mg/kg/day for the treatment of complicated skin and soft tissue infections (cSSTI) and at a dose of 6 mg/kg/day ...